Dear Sir,
We want to report a profound, reversible reduction in p50 (N35–p50) amplitude in the
pattern Electroretinogram (PERG) of eyes treated with low dose (0.01%) atropine eye
drops without a significant change in the implicit time.
Recently, 0.01% atropine eye drops has become popular as first-line treatment for
progressive myopia in children.[1] Potential side effects of topical atropine eye
drops include pupillary mydriasis, reduced accommodation, light sensitivity, near
vision blur, headache, ocular allergy, periocular dermatitis, angle closure glaucoma,
drug-related retinal toxicity, and mydriasis-related phototoxicity. The investigators
of Atropine in the Treatment of Myopia studies have reported a lack of retinal toxicity
with long term (2 years) use of atropine eye drops in children with progressive myopia
using multifocal ERG (MFERG) testing.[2
3]
We obtained full field ERG (FFERG), PERG, and MFERG from the eyes of the authors (subject
1, MK, male, 43 years old, high myopia with best corrected vision 20/20 and subject
2, NK, female, 32 years old, emmetrope with best corrected vision 20/20). Both the
subjects underwent ERGs on a Roland Consult ERG machine (Brandenburg, Germany) and
Dawson, Trick, Litzkow (DTL) electrodes using International Society for Clinical Electrophysiology
of Vision (ISCEV) standard protocol. After obtaining the baseline ERGs, one drop of
0.01% atropine eye drop (Myopin®, Appasamy, Chennai, India) was instilled four times
at an interval of 1 min in the right eye of subject 1 and left eye of subject 2. The
other eye was used as a “control.” Forty five minutes after after application of 0.01%
atropine eye drops, ERGs were repeated using the same protocol. This was immediately
followed by anterior segment optical coherence tomography (ASOCT) using Cirrus HD-OCT
(Zeiss, Germany) to document the biometric changes. As such, the ERG technician and
the electrophysiologist (DB) were unaware about which eye had received atropine eye
drops.
One week later ERGs were re-recorded. The “control” eye of each subject (as designated
above) was dilated with two drops of tropicamide 0.8%-phenylephrine 5% eye drops (Itrop
plus®, Cipla, Mumbai, India). After 45 min, the ERGs were obtained from both the eyes
to assess the effect of mydriasis and loss of accommodation sans “atropine effect”.
No significant changes were found with either Myopin® or Itrop plus® on FFERG and
MFERG. PERGs demonstrated profound, reversible reduction in the amplitude of P50 (N35-P50),
more in the Myopin® treated eyes than Itrop plus® treated eyes [Table 1 and Fig. 1].
The biometric changes on ASOCT as well as P50 changes were more profound in subject
1, who had light colored iris compared to subject 2.
Table 1
Biometric changes (anterior segment OCT) and changes in PERG after Myopin® eye drops
and Itrop plus® eye drops
Baseline
After Myopin®
Baseline
After Itrop plus®
Subject 1
P50 (mv)
2.58
0.6
2.83
1.05
Pupil (mm)
3.239
6.284
3.230
6.251
Anterior chamber volume (mm2)
24.79
28.79
24.26
29.17
Subject 2
P50 (mv)
4.10
2.51
3.31
2.87
Pupil (mm)
3.264
4.396
3.790
4.861
Anterior chamber volume (mm2)
21.20
20.27
20.94
22.58
Figure 1
PERGs of subjects 1 and 2 before and after 0.01% atropine eye drops. (a) Baseline
PERG of subject 1. (b) After 0.01% atropine eye drops demonstrating a decrease in
P50 amplitude from 2.58 μv to 600 nv on small checker board pattern. (c) Baseline
PERG of subject 2. (d) After 0.01% atropine eye drops demonstrating a decrease in
P50 amplitude from 4.10 μv to 2.51 μv on small checker board pattern
Atropine is a potent anticholinergic drug and a variety of vertebrate species possess
cholinergic transmitting mechanisms in their retinae.[4] The acetylcholine-receptors
are detected in the outer and inner plexiform layers of the birds and mammals with
a considerable interspecies variability in its distribution.[4] Compared to avian
retinae, mammalian retinae have higher cholinergic activity in the inner plexiform
layer than the outer plexiform layer. The PERG finding discovered by us could be a
result of an alteration in the signal transmission in the retina or due to blurring
induced due to cycloplegia and mydriasis or both.
Further studies are necessary to assess the macular functions of children treated
with low dose atropine eye drops.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.